Chicago, March 20 – Tempus announced today it has raised an additional $80M in financing. The round included existing investors, New Enterprise Associates and Revolution Growth, along with new investors Kinship Trust Company and funds advised by T. Rowe Price Associates, Inc. The additional funds will be used to further grow and scale the company’s clinical and molecular analytic platform. With this close, the company has raised $210 million to date.
“Tempus was born out of frustration with a health care system that too often let powerful data and real world evidence go to waste,” said Eric Lefkofsky, founder and CEO at Tempus. “Given the breadth and scale of our current data set, we’re in a unique position to help usher in an era of precision medicine to support patients battling disease.”
While personalized medicine is happening in isolation, it is nearly impossible to scale these efforts without centralizing vast amounts of phenotypic, therapeutic, and molecular data. Tempus has addressed this by building an ecosystem to collect, cleanse, analyze, and apply data solutions to oncology, and healthcare more broadly, through a suite of products that are driving real-time, clinical decision support and cutting-edge research.
In addition to working with independent oncologists and hospital systems across the country, including nearly half of all Academic Medical Centers in the United States, the company recently entered in an agreement with CancerLinQ, a subsidiary of the American Society of Clinical Oncology (ASCO), which accounts for more than 2,000 medical oncologists who have contributed millions of cancer patient records to date.